Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 290

1.

Discovery of potent 4-aminoquinoline hydrazone inhibitors of NRH:quinoneoxidoreductase-2 (NQO2).

Hussein B, Ikhmais B, Kadirvel M, Magwaza RN, Halbert G, Bryce RA, Stratford IJ, Freeman S.

Eur J Med Chem. 2019 Aug 27;182:111649. doi: 10.1016/j.ejmech.2019.111649. [Epub ahead of print]

PMID:
31514018
2.

Negative Cooperativity in NAD(P)H Quinone Oxidoreductase 1 (NQO1).

Megarity CF, Abdel-Aal Bettley H, Caraher MC, Scott KA, Whitehead RC, Jowitt TA, Gutierrez A, Bryce RA, Nolan KA, Stratford IJ, Timson DJ.

Chembiochem. 2019 Jun 5. doi: 10.1002/cbic.201900313. [Epub ahead of print]

PMID:
31165578
3.

Evaluating the Efficiency of Hyaluronic Acid for Tumor Targeting via CD44.

Spadea A, Rios de la Rosa JM, Tirella A, Ashford MB, Williams KJ, Stratford IJ, Tirelli N, Mehibel M.

Mol Pharm. 2019 Jun 3;16(6):2481-2493. doi: 10.1021/acs.molpharmaceut.9b00083. Epub 2019 May 1.

PMID:
31013093
4.

Statin-induced metabolic reprogramming in head and neck cancer: a biomarker for targeting monocarboxylate transporters.

Mehibel M, Ortiz-Martinez F, Voelxen N, Boyers A, Chadwick A, Telfer BA, Mueller-Klieser W, West CM, Critchlow SE, Williams KJ, Stratford IJ.

Sci Rep. 2018 Nov 14;8(1):16804. doi: 10.1038/s41598-018-35103-1.

5.

Corrigendum to "Preclinical anti-cancer activity and multiple mechanisms of action of a cationic silver complex bearing N-heterocyclic carbene ligands" [Canc. Lett. 403 (2017) 98-107].

Allison SJ, Sadiq M, Baronou E, Cooper PA, Dunnill C, Georgopoulos NT, Latif A, Shepherd S, Shnyder SD, Stratford IJ, Wheelhouse RT, Willans CE, Phillips RM.

Cancer Lett. 2018 Sep 1;431:247. doi: 10.1016/j.canlet.2018.06.022. Epub 2018 Jun 19. No abstract available.

6.

Evaluation of analogues of furan-amidines as inhibitors of NQO2.

Alnabulsi S, Hussein B, Santina E, Alsalahat I, Kadirvel M, Magwaza RN, Bryce RA, Schwalbe CH, Baldwin AG, Russo I, Stratford IJ, Freeman S.

Bioorg Med Chem Lett. 2018 May 1;28(8):1292-1297. doi: 10.1016/j.bmcl.2018.03.025. Epub 2018 Mar 12.

PMID:
29567345
7.

Monocarboxylate Transporter 1 (MCT1) is an independent prognostic biomarker in endometrial cancer.

Latif A, Chadwick AL, Kitson SJ, Gregson HJ, Sivalingam VN, Bolton J, McVey RJ, Roberts SA, Marshall KM, Williams KJ, Stratford IJ, Crosbie EJ.

BMC Clin Pathol. 2017 Dec 28;17:27. doi: 10.1186/s12907-017-0067-7. eCollection 2017.

8.

Corrigendum: Expression of NAD(P)H quinone dehydrogenase 1 (NQO1) is increased in the endometrium of women with endometrial cancer and women with polycystic ovary syndrome.

Atiomo W, Shafiee MN, Chapman C, Metzler VM, Abouzeid J, Latif A, Chadwick A, Kitson S, Sivalingam VN, Stratford IJ, Rutland CS, Persson JL, Ødum N, Fuentes-Utrilla P, Jeyapalan JN, Heery DM, Crosbie EJ, Mongan NP.

Clin Endocrinol (Oxf). 2017 Dec;87(6):886. doi: 10.1111/cen.13515. No abstract available.

PMID:
29160590
9.

Akt inhibition improves long-term tumour control following radiotherapy by altering the microenvironment.

Searle EJ, Telfer BA, Mukherjee D, Forster DM, Davies BR, Williams KJ, Stratford IJ, Illidge TM.

EMBO Mol Med. 2017 Dec;9(12):1646-1659. doi: 10.15252/emmm.201707767.

10.

Expression of NAD(P)H quinone dehydrogenase 1 (NQO1) is increased in the endometrium of women with endometrial cancer and women with polycystic ovary syndrome.

Atiomo W, Shafiee MN, Chapman C, Metzler VM, Abouzeid J, Latif A, Chadwick A, Kitson S, Sivalingam VN, Stratford IJ, Rutland CS, Persson JL, Ødum N, Fuentes-Utrilla P, Jeyapalan JN, Heery DM, Crosbie EJ, Mongan NP.

Clin Endocrinol (Oxf). 2017 Nov;87(5):557-565. doi: 10.1111/cen.13436. Epub 2017 Aug 18. Erratum in: Clin Endocrinol (Oxf). 2017 Dec;87(6):886.

11.

Preclinical anti-cancer activity and multiple mechanisms of action of a cationic silver complex bearing N-heterocyclic carbene ligands.

Allison SJ, Sadiq M, Baronou E, Cooper PA, Dunnill C, Georgopoulos NT, Latif A, Shepherd S, Shnyder SD, Stratford IJ, Wheelhouse RT, Willans CE, Phillips RM.

Cancer Lett. 2017 Sep 10;403:98-107. doi: 10.1016/j.canlet.2017.04.041. Epub 2017 Jun 15. Erratum in: Cancer Lett. 2018 Sep 1;431:247.

12.

Chitosan/Hyaluronic Acid Nanoparticles: Rational Design Revisited for RNA Delivery.

Lallana E, Rios de la Rosa JM, Tirella A, Pelliccia M, Gennari A, Stratford IJ, Puri S, Ashford M, Tirelli N.

Mol Pharm. 2017 Jul 3;14(7):2422-2436. doi: 10.1021/acs.molpharmaceut.7b00320. Epub 2017 Jun 19.

PMID:
28597662
13.

The CD44-Mediated Uptake of Hyaluronic Acid-Based Carriers in Macrophages.

Rios de la Rosa JM, Tirella A, Gennari A, Stratford IJ, Tirelli N.

Adv Healthc Mater. 2017 Feb;6(4). doi: 10.1002/adhm.201601012. Epub 2016 Dec 19.

PMID:
27990775
14.

Clinical development of new drug-radiotherapy combinations.

Sharma RA, Plummer R, Stock JK, Greenhalgh TA, Ataman O, Kelly S, Clay R, Adams RA, Baird RD, Billingham L, Brown SR, Buckland S, Bulbeck H, Chalmers AJ, Clack G, Cranston AN, Damstrup L, Ferraldeschi R, Forster MD, Golec J, Hagan RM, Hall E, Hanauske AR, Harrington KJ, Haswell T, Hawkins MA, Illidge T, Jones H, Kennedy AS, McDonald F, Melcher T, O'Connor JP, Pollard JR, Saunders MP, Sebag-Montefiore D, Smitt M, Staffurth J, Stratford IJ, Wedge SR; NCRI CTRad Academia-Pharma Joint Working Group.

Nat Rev Clin Oncol. 2016 Oct;13(10):627-42. doi: 10.1038/nrclinonc.2016.79. Epub 2016 Jun 1.

15.

Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy.

Dovedi SJ, Adlard AL, Ota Y, Murata M, Sugaru E, Koga-Yamakawa E, Eguchi K, Hirose Y, Yamamoto S, Umehara H, Honeychurch J, Cheadle EJ, Hughes G, Jewsbury PJ, Wilkinson RW, Stratford IJ, Illidge TM.

Oncotarget. 2016 Mar 29;7(13):17035-46. doi: 10.18632/oncotarget.7928.

16.

Non-symmetrical furan-amidines as novel leads for the treatment of cancer and malaria.

Alnabulsi S, Santina E, Russo I, Hussein B, Kadirvel M, Chadwick A, Bichenkova EV, Bryce RA, Nolan K, Demonacos C, Stratford IJ, Freeman S.

Eur J Med Chem. 2016 Mar 23;111:33-45. doi: 10.1016/j.ejmech.2016.01.022. Epub 2016 Jan 21.

PMID:
26854376
17.

Radiation enhances the therapeutic effect of Banoxantrone in hypoxic tumour cells with elevated levels of nitric oxide synthase.

Mehibel M, Singh S, Cowen RL, Williams KJ, Stratford IJ.

Oncol Rep. 2016 Apr;35(4):1925-32. doi: 10.3892/or.2016.4555. Epub 2016 Jan 13.

18.

Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport.

Bola BM, Chadwick AL, Michopoulos F, Blount KG, Telfer BA, Williams KJ, Smith PD, Critchlow SE, Stratford IJ.

Mol Cancer Ther. 2014 Dec;13(12):2805-16. doi: 10.1158/1535-7163.MCT-13-1091. Epub 2014 Oct 3.

19.

Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.

Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, Stratford IJ, Poon E, Morrow M, Stewart R, Jones H, Wilkinson RW, Honeychurch J, Illidge TM.

Cancer Res. 2014 Oct 1;74(19):5458-68. doi: 10.1158/0008-5472.CAN-14-1258.

20.

The two common polymorphic forms of human NRH-quinone oxidoreductase 2 (NQO2) have different biochemical properties.

Megarity CF, Gill JR, Caraher MC, Stratford IJ, Nolan KA, Timson DJ.

FEBS Lett. 2014 May 2;588(9):1666-72. doi: 10.1016/j.febslet.2014.02.063. Epub 2014 Mar 12.

21.

Emerging opportunities for the combination of molecularly targeted drugs with radiotherapy.

Searle EJ, Illidge TM, Stratford IJ.

Clin Oncol (R Coll Radiol). 2014 May;26(5):266-76. doi: 10.1016/j.clon.2014.02.006. Epub 2014 Mar 4. Review.

PMID:
24602563
22.

A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models.

Adlard AL, Dovedi SJ, Telfer BA, Koga-Yamakawa E, Pollard C, Honeychurch J, Illidge TM, Murata M, Robinson DT, Jewsbury PJ, Wilkinson RW, Stratford IJ.

Int J Cancer. 2014 Aug 15;135(4):820-9. doi: 10.1002/ijc.28711. Epub 2014 Jan 17.

23.

A synthetic approach to novel carvotacetone and antheminone analogues with anti-tumour activity.

Christou S, Ozturk E, Pritchard RG, Quayle P, Stratford IJ, Whitehead RC, Williams KF.

Bioorg Med Chem Lett. 2013 Sep 15;23(18):5066-9. doi: 10.1016/j.bmcl.2013.07.041. Epub 2013 Jul 26.

PMID:
23937978
24.

Inhibition of carbonic anhydrase activity modifies the toxicity of doxorubicin and melphalan in tumour cells in vitro.

Gieling RG, Parker CA, De Costa LA, Robertson N, Harris AL, Stratford IJ, Williams KJ.

J Enzyme Inhib Med Chem. 2013 Apr;28(2):360-9. doi: 10.3109/14756366.2012.736979. Epub 2012 Nov 19.

PMID:
23163664
25.

Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma.

Dovedi SJ, Melis MH, Wilkinson RW, Adlard AL, Stratford IJ, Honeychurch J, Illidge TM.

Blood. 2013 Jan 10;121(2):251-9. doi: 10.1182/blood-2012-05-432393. Epub 2012 Oct 18.

PMID:
23086756
26.

Electron-affinic sensitization VII. A correlation between structures, one-electron reduction potentials, and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers. 1976.

Adams GE, Flockhart IR, Smithen CE, Stratford IJ, Wardman P, Watts ME.

Radiat Res. 2012 Aug;178(2):AV183-9. No abstract available.

PMID:
22870968
27.

In silico screening reveals structurally diverse, nanomolar inhibitors of NQO2 that are functionally active in cells and can modulate NF-κB signaling.

Nolan KA, Dunstan MS, Caraher MC, Scott KA, Leys D, Stratford IJ.

Mol Cancer Ther. 2012 Jan;11(1):194-203. doi: 10.1158/1535-7163.MCT-11-0543. Epub 2011 Nov 16.

28.

Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.

Senra JM, Telfer BA, Cherry KE, McCrudden CM, Hirst DG, O'Connor MJ, Wedge SR, Stratford IJ.

Mol Cancer Ther. 2011 Oct;10(10):1949-58. doi: 10.1158/1535-7163.MCT-11-0278. Epub 2011 Aug 8.

29.

Novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2): crystal structures, biochemical activity, and intracellular effects of imidazoacridin-6-ones.

Dunstan MS, Barnes J, Humphries M, Whitehead RC, Bryce RA, Leys D, Stratford IJ, Nolan KA.

J Med Chem. 2011 Oct 13;54(19):6597-611. doi: 10.1021/jm200416e. Epub 2011 Sep 13.

PMID:
21859103
30.

Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers.

Harrington KJ, Billingham LJ, Brunner TB, Burnet NG, Chan CS, Hoskin P, Mackay RI, Maughan TS, Macdougall J, McKenna WG, Nutting CM, Oliver A, Plummer R, Stratford IJ, Illidge T.

Br J Cancer. 2011 Aug 23;105(5):628-39. doi: 10.1038/bjc.2011.240. Epub 2011 Jul 19. Review. No abstract available.

31.

In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2).

Nolan KA, Caraher MC, Humphries MP, Bettley HA, Bryce RA, Stratford IJ.

Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. doi: 10.1016/j.bmcl.2010.10.070. Epub 2010 Oct 21.

PMID:
21074425
32.

Inhibitors of NQO1: identification of compounds more potent than dicoumarol without associated off-target effects.

Scott KA, Barnes J, Whitehead RC, Stratford IJ, Nolan KA.

Biochem Pharmacol. 2011 Feb 1;81(3):355-63. doi: 10.1016/j.bcp.2010.10.011. Epub 2010 Oct 21.

PMID:
20970406
33.

Testing for hypoxia in forearm skin of patients with systemic sclerosis, assessed by pimonidazole.

Herrick AL, Gorodkin R, Jeziorska M, Stratford IJ.

J Rheumatol. 2010 Sep;37(9):1968-9. doi: 10.3899/jrheum.100174. No abstract available.

PMID:
20810526
34.

Pharmacological inhibitors of NAD(P)H quinone oxidoreductase, NQO1: structure/activity relationships and functional activity in tumour cells.

Nolan KA, Scott KA, Barnes J, Doncaster J, Whitehead RC, Stratford IJ.

Biochem Pharmacol. 2010 Oct 1;80(7):977-81. doi: 10.1016/j.bcp.2010.06.024. Epub 2010 Jun 23.

PMID:
20599803
35.

The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy.

Lunt SJ, Cawthorne C, Ali M, Telfer BA, Babur M, Smigova A, Julyan PJ, Price PM, Stratford IJ, Bloomer WD, Papadopoulou MV, Williams KJ.

Br J Cancer. 2010 Jul 13;103(2):201-8. doi: 10.1038/sj.bjc.6605753. Epub 2010 Jun 29.

36.

Guidelines for the welfare and use of animals in cancer research.

Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA; Committee of the National Cancer Research Institute.

Br J Cancer. 2010 May 25;102(11):1555-77. doi: 10.1038/sj.bjc.6605642.

37.

Radiotherapy research priorities for the UK.

Maughan TS, Illidge TM, Hoskin P, McKenna WG, Brunner TB, Stratford IJ, Harrington KJ, Plummer R, Billingham LJ, Nutting C, Burnet NG, Mackay RI, Oliver A, Young C, Chan CS; NCRI Clinical and Translational Radiotherapy Research Working Group.

Clin Oncol (R Coll Radiol). 2010 Oct;22(8):707-9. doi: 10.1016/j.clon.2010.03.006. Epub 2010 Apr 2. No abstract available.

PMID:
20363111
38.

Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2.

Nolan KA, Humphries MP, Bryce RA, Stratford IJ.

Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6. doi: 10.1016/j.bmcl.2010.03.051. Epub 2010 Mar 15.

PMID:
20356739
39.

Spectrophotometric analysis of nucleic acids: oxygenation-dependent hyperchromism of DNA.

Doshi R, Day PJ, Carampin P, Blanch E, Stratford IJ, Tirelli N.

Anal Bioanal Chem. 2010 Mar;396(6):2331-9. doi: 10.1007/s00216-010-3461-x. Epub 2010 Feb 19.

PMID:
20169336
40.

Site and strain-specific variation in gut microbiota profiles and metabolism in experimental mice.

Friswell MK, Gika H, Stratford IJ, Theodoridis G, Telfer B, Wilson ID, McBain AJ.

PLoS One. 2010 Jan 5;5(1):e8584. doi: 10.1371/journal.pone.0008584.

41.

Triazoloacridin-6-ones as novel inhibitors of the quinone oxidoreductases NQO1 and NQO2.

Nolan KA, Humphries MP, Barnes J, Doncaster JR, Caraher MC, Tirelli N, Bryce RA, Whitehead RC, Stratford IJ.

Bioorg Med Chem. 2010 Jan 15;18(2):696-706. doi: 10.1016/j.bmc.2009.11.059. Epub 2009 Dec 21.

PMID:
20036559
42.

Glucocorticoid receptor over-expression promotes human small cell lung cancer apoptosis in vivo and thereby slows tumor growth.

Sommer P, Cowen RL, Berry A, Cookson A, Telfer BA, Williams KJ, Stratford IJ, Kay P, White A, Ray DW.

Endocr Relat Cancer. 2010 Feb 18;17(1):203-13. doi: 10.1677/ERC-09-0241. Print 2010 Mar.

43.

In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts.

Williams KJ, Albertella MR, Fitzpatrick B, Loadman PM, Shnyder SD, Chinje EC, Telfer BA, Dunk CR, Harris PA, Stratford IJ.

Mol Cancer Ther. 2009 Dec;8(12):3266-75. doi: 10.1158/1535-7163.MCT-09-0396.

44.

Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1).

Nolan KA, Doncaster JR, Dunstan MS, Scott KA, Frenkel AD, Siegel D, Ross D, Barnes J, Levy C, Leys D, Whitehead RC, Stratford IJ, Bryce RA.

J Med Chem. 2009 Nov 26;52(22):7142-56. doi: 10.1021/jm9011609.

PMID:
19877692
45.

The mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) enhances the radiation responsiveness of lung and colorectal tumor xenografts.

Shannon AM, Telfer BA, Smith PD, Babur M, Logie A, Wilkinson RW, Debray C, Stratford IJ, Williams KJ, Wedge SR.

Clin Cancer Res. 2009 Nov 1;15(21):6619-29. doi: 10.1158/1078-0432.CCR-08-2958. Epub 2009 Oct 20.

46.

Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells.

Roberts DL, Williams KJ, Cowen RL, Barathova M, Eustace AJ, Brittain-Dissont S, Tilby MJ, Pearson DG, Ottley CJ, Stratford IJ, Dive C.

Br J Cancer. 2009 Oct 20;101(8):1290-7. doi: 10.1038/sj.bjc.6605311. Epub 2009 Sep 15.

47.

The impact of intracellular generation of nitric oxide on the radiation response of human tumor cells.

Singh S, Cowen RL, Chinje EC, Stratford IJ.

Radiat Res. 2009 May;171(5):572-80. doi: 10.1667/RR1640.1.

PMID:
19580492
48.

Effects of cytokine-induced macrophages on the response of tumor cells to banoxantrone (AQ4N).

Mehibel M, Singh S, Chinje EC, Cowen RL, Stratford IJ.

Mol Cancer Ther. 2009 May;8(5):1261-9. doi: 10.1158/1535-7163.MCT-08-0927. Epub 2009 May 12.

49.

Inhibition of vascular endothelial growth factor signalling using cediranib (RECENTIN; AZD2171) enhances radiation response and causes substantial physiological changes in lung tumour xenografts.

Williams KJ, Telfer BA, Shannon AM, Babur M, Stratford IJ, Wedge SR.

Br J Radiol. 2008 Oct;81 Spec No 1:S21-7. doi: 10.1259/bjr/59853976.

PMID:
18819995
50.

Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1).

Yan C, Kepa JK, Siegel D, Stratford IJ, Ross D.

Mol Pharmacol. 2008 Dec;74(6):1657-65. doi: 10.1124/mol.108.050401. Epub 2008 Sep 15.

Supplemental Content

Loading ...
Support Center